The altered ratio of membrane-bound to secreted PD-L1 could play a decisive role in the reduced overall survival observed in many tumor diseases with elevated SRSF2 expression—regardless of whether a therapy with mAbs against the PD-1/PD-L1 ICP axis is applied, because it also involves the inhibition of tumor-infiltrating immune effector cells. This evidence concerns the gene SRSF2 and neoplasm.